SALT LAKE CITY--Ventana Genetics here announced that M. Scott Salka is the biotech company's new CEO. Salka joined Ventana from genomics company Sequana Therapeutics, where he was vice president of operations and chief financial officer. At Sequana, Salka directed strategic planning and corporate development efforts, which included raising capital and structuring industry collaborations. He participated in Sequana's startup in 1993 and was instrumental in raising over $25 million in three rounds of private funding and nearly $50 million in two public equity financings, as well as negotiating four industry collaborations worth up to $250 million.
Former Sequana CFO Joins Ventana Genetics
Dec 21, 1998